Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
Royal Netherlands Academy of Arts and Sciences · University Medical Center Utrecht · +7 more institutions
Abstract
We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors. Taken together, the work presented here provides a platform to…
Citation impact
- FWCI
- 19.57
- Percentile
- 100%
- References
- 40
Authors
22- EDElse DriehuisCorresponding
Royal Netherlands Academy of Arts and Sciences, University Medical Center Utrecht, Oncode Institute
- AVArne van Hoeck
University Medical Center Utrecht, Oncode Institute
- KMKat Moore
The Netherlands Cancer Institute, Oncode Institute
- SKSigrid Kolders
Royal Netherlands Academy of Arts and Sciences, University Medical Center Utrecht, Oncode Institute
- HEHayley E. Francies
Wellcome Sanger Institute
Topics & keywords
- Pancreatic cancer
- Organoid
- Medicine
- Personalized medicine
- Pancreas
- Cancer
- Drug
- Cancer research
- Good health and well-being